| 01-12-2010 11:05 AM CET - Health & Medicine |
|
Stem Cell Company t2cure Appoints Dr Petra Rueck and Susanne Knigge as Co-CEOs
Press release from: t2cure GmbH
PR Agency: Frank Butschbacher Investor Relations & Communications
(openPR) - Frankfurt, Germany, January 11, 2010 – t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based therapies, announced today that it has appointed Dr. Petra Rueck and Mrs. Susanne Knigge to Co-CEO’s, effective January 1, 2010. Dr. Manfred Ruediger has laid down his assignment as CEO and Managing Director of t2cure GmbH to join Life Sciences Partners, the European life sciences venture group, as a partner. The Company also announced that its lead product is now available for patients suffering from cardiovascular disease.
“I am proud that in 2009 t2cure continued to grow the position of our stem cell-based therapy in the market and that this product is currently used for the treatment of patients with acute myocardial infarction in several major hospitals in Germany,” commented Dr. Ruediger. “Accordingly, t2cure has consistently increased its sales with this product and anticipates further growth.”
“The efficacy and safety of our lead product t2c001 has only recently been confirmed by the publication of 2-year data from our Phase II-trial in acute myocardial infarction,” said Dr. Rueck, Co-CEO of t2cure. “We have recently initiated the certification process for our lead product under the EMEA regulation for Advanced Therapy Medicinal Products. t2cure is one of the first companies worldwide to apply for EMEA certification. Certification will bring us significantly closer to a Centralized European Approval for our lead product, and we expect the certification process to be completed in early 2010.”
Before being appointed to CEO, Dr. Petra Rueck served as Head Clinical Operations of t2cure since 2007. Susanne Knigge was a managing director of t2cure between 2005 and 2008 and supported the Company as legal counsel from 2008 to 2009. Dr. Ruediger was CEO of t2cure from 2006 through 2009 and will remain a shareholder and a consultant to the Company.
About t2cure GmbH
t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease), non-ischemic heart failure and peripheral arterial occlusive disease. The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development.
t2cure is privately financed with EF Investments (Luxembourg) S.a.r.l. as lead investor.
Company contact:
Dr. Petra Rueck, CEO
t2cure GmbH
Bettinastrasse 35-37
D-60325 Frankfurt am Main
Tel: +49-69-75 61 46 87 0
Fax: +49-69-75 61 46 87 9
Email: info@t2cure.com
www.t2cure.com
Media contact:
Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43-650-7844940
office@butschbacher.net
“I am proud that in 2009 t2cure continued to grow the position of our stem cell-based therapy in the market and that this product is currently used for the treatment of patients with acute myocardial infarction in several major hospitals in Germany,” commented Dr. Ruediger. “Accordingly, t2cure has consistently increased its sales with this product and anticipates further growth.”
“The efficacy and safety of our lead product t2c001 has only recently been confirmed by the publication of 2-year data from our Phase II-trial in acute myocardial infarction,” said Dr. Rueck, Co-CEO of t2cure. “We have recently initiated the certification process for our lead product under the EMEA regulation for Advanced Therapy Medicinal Products. t2cure is one of the first companies worldwide to apply for EMEA certification. Certification will bring us significantly closer to a Centralized European Approval for our lead product, and we expect the certification process to be completed in early 2010.”
Before being appointed to CEO, Dr. Petra Rueck served as Head Clinical Operations of t2cure since 2007. Susanne Knigge was a managing director of t2cure between 2005 and 2008 and supported the Company as legal counsel from 2008 to 2009. Dr. Ruediger was CEO of t2cure from 2006 through 2009 and will remain a shareholder and a consultant to the Company.
About t2cure GmbH
t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease), non-ischemic heart failure and peripheral arterial occlusive disease. The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development.
t2cure is privately financed with EF Investments (Luxembourg) S.a.r.l. as lead investor.
Company contact:
Dr. Petra Rueck, CEO
t2cure GmbH
Bettinastrasse 35-37
D-60325 Frankfurt am Main
Tel: +49-69-75 61 46 87 0
Fax: +49-69-75 61 46 87 9
Email: info@t2cure.com
www.t2cure.com
Media contact:
Frank Butschbacher
Investor Relations & Communications
www.butschbacher.net
+43-650-7844940
office@butschbacher.net
News-ID: 116169
|
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
t2cure GmbH
No further reports available
Comments about openPR
Your portal is fast, simple, and easy to use. Others may have more functions but they also demand more editing time, you have to preformat the text in order to achieve a good result etc.
I think openPR is really fantastic!
Andreas Knepper, wallmedien AG
I think openPR is really fantastic!
Andreas Knepper, wallmedien AG